title: Gonadotropin-releasing hormone agonist or human chorionic gonadotropin for final oocyte maturation in an oocyte donor program.
abstract: OBJECTIVE
  To compare leuprolide acetate to hCG as the trigger for final oocyte maturation in oocyte donor cycles.
  
  
  METHODS
  Retrospective review.
  
  
  METHODS
  Academic IVF donor program.
  
  
  METHODS
  Thirty-two healthy oocyte donors aged 21-33 years with adequate ovarian reserve.
  
  
  METHODS
  Donors were down-regulated with cetrorelix and received either leuprolide acetate (n = 12) or hCG (n = 20) for final oocyte maturation.
  
  
  METHODS
  Embryo number, embryo quality, fertilization, implantation, clinical pregnancy, and ovarian hyperstimulation syndrome rates.
  
  
  RESULTS
  The numbers of total oocytes (23 vs. 15), mature (metaphase II) oocytes (22 vs. 13), embryos (15 vs. 10), and cryopreserved embryos (12 vs. 6) per treatment cycle were significantly greater in the leuprolide arm than in the hCG arm. Fertilization rates (73% vs. 78%), implantation rates (30% vs. 29%), and clinical pregnancy rates (40% vs. 50%) were not statistically different between the arms. There were no cases of ovarian hyperstimulation syndrome.
  
  
  CONCLUSIONS
  Leuprolide acetate-triggered oocyte donor cycles yielded similar fertilization, implantation, and clinical pregnancy rates to hCG-triggered cycles.
authors.affiliation: Reproductive Endocrinology and Infertility, Magee Women's Hospital, Pittsburgh, Pennsylvania 15213, USA.
authors.forename: Teresa M
authors.initials: TM
authors.lastname: Erb
authors.forename: Wendy
authors.initials: W
authors.lastname: Vitek
authors.forename: Anthony N G
authors.initials: AN
authors.lastname: Wakim
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000627:therapeutic use*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000494:pharmacology; D016729:Leuprolide / Q000627:therapeutic use*; D018587:Oocyte Donation; D009865:Oocytes / Q000187:drug effects / Q000502:physiology*; D006080:Ovarian Follicle / Q000166:cytology / Q000187:drug effects; D010062:Ovulation Induction; D011247:Pregnancy; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D006063:Chorionic Gonadotropin; D006727:Hormone Antagonists; D036341:Intercellular Signaling Peptides and Proteins; C018355:intraovarian peptides; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D005640:Follicle Stimulating Hormone; D016729:Leuprolide; C062876:cetrorelix